BeyondSpring (NASDAQ:BYSI) Bolsa

BeyondSpring

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.

BeyondSpring Inc

Earnings

Earnings Beats

News

STOK

Stoke Therapeutics Q1 EPS $1.90 Beats $(0.42) Estimate, Sales $158.57M Beat $7.61M Estimate

IMTX

Immatics Q1 Sales $20.10M Beat $13.96M Estimate

COIN: 10% &#x7C; <a href="https://www.benzinga.com//node/45362657">Coinbase Global shares are trading higher it was announced that the company will join the S&amp;P 500, effective before the opening of trading on Monday, May 19.</a>
&nbsp;
OPRX: 24% &#x7C; <a href="https://www.benzinga.com//node/45360714">OptimizeRx shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sale guidance with its midpoint above estimates.</a>
&nbsp;
CNSP: 160% &#x7C; <a href="https://www.benzinga.com//node/45371340">CNS Pharmaceuticals Announces Transfer Of Orphan Drug Designation For TPI 287 From Cortice Biosciences, Inc.</a>

Movers

Trading Ideas

CNSP

COIN

OPRX

Market-Moving News for May 13th

United Airlines Unveils Upgraded 787 Interiors With Business Class Suites, Caviar Service, And US Seatback Screens

BK Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BKTI#AMEX">BKTI</a>) FY2025 expected to be more than $2.40 vs $3.38 Est..

Guidance

BKTI

BK Technologies FY2025  Expected To Be More Than $2.40 vs $3.38 Est

SLAB

Silicon Laboratories Q1 Adj. EPS $(0.08) Beats $(0.09) Estimate, Sales $178.00M Beat $177.47M Estimate

Galaxy Digital Hldgs (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GLXY#TSX">GLXY</a>) reported quarterly losses of $(0.86) per share. This is a 178.18 percent decrease over earnings of $1.10 per share from the same period last year. The company reported $12.86 million in sales this quarter. This is a 30.81 percent increase over sales of $9.83 million the same period last year.

TSX:GLXY

Galaxy Digital Hldgs Q1 EPS $(0.86) Down From $1.10 YoY, Sales $12.86M Up From $9.83M YoY

Instil Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) reported quarterly losses of $(1.32) per share which beat the analyst consensus estimate of $(2.59) by 49.03 percent. This is a 44.77 percent increase over losses of $(2.39) per share from the same period last year.

Instil Bio Q1 Adj. EPS $(1.32) Beats $(2.59) Estimate

Earnings Misses

PASG

Passage Bio Q1 EPS $(0.25) Misses $(0.23) Estimate

BK Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BKTI#AMEX">BKTI</a>) FY2025 expected to be more than $2.80 vs $3.38 Est..

BK Technologies FY2025  Expected To Be More Than $2.80 vs $3.38 Est

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) with a Buy and maintains $55 price target.

Price Target

Reiteration

Analyst Ratings

URGN

HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $55 Price Target

Perion Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PERI#NASDAQ">PERI</a>) raises FY2025 sales outlook from $400.00 million-$420.00 million to $430.00 million-$450.00 million vs $409.92 million estimate.

PERI

Perion Network Raises FY2025 Sales Guidance from $400.00M-$420.00M to $430.00M-$450.00M vs $409.92M Est

RGNX

REGENXBIO Announces FDA Acceptance And Priority Review Of BLA For RGX-121 For Mucopolysaccharidosis II

Bilibili Inc. ("Bilibili" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>), an iconic brand and a leading video community for young generations in China, today announced that it is notifying holders of its 1.25% Convertible Senior Notes due 2027 (CUSIP No. 090040AD8) (the "Notes") that, pursuant to the Indenture dated as of June 2, 2020 (the "Indenture") relating to the Notes by and between the Company and Deutsche Bank Trust Company Americas, as trustee, each holder has the right, at the option of such holder, to require the Company to repurchase all of such holder's Notes or any portion thereof that is an integral multiple of US$1,000 principal amount for cash on June 15, 2025 (the "2025 Repurchase Right"). Holders of the Notes may exercise the 2025 Repurchase Right from 12:01 a.m., New York City time, on Wednesday, May 14, 2025 (the "Repurchase Open Time") until 5:00 p.m., New York City time, on Thursday, June 12, 2025 (the "Repurchase Expiration Time").

Buybacks

BILI

Bilibili Offers to Buy Back 2027 Convertible Notes as June 2025 Repurchase Window Opens

Perion Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PERI#NASDAQ">PERI</a>) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $(0.09) by 222.22 percent. This is a 75 percent decrease over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $89.34 million which beat the analyst consensus estimate of $86.80 million by 2.93 percent. This is a 43.39 percent decrease over sales of $157.82 million the same period last year.

Perion Network Q1 Adj. EPS $0.11 Beats $(0.09) Estimate, Sales $89.34M Beat $86.80M Estimate

Biotech

General

ATAI

atai Life Sciences Doses First Patient Dosed In Phase 2 Study Of EMP-01 For Social Anxiety Disorder; Topline Data anticipate In Q1 Of 2026

In vivo CRISPR Editing Results in Functional Upregulation of a Liver Target Protein and Meaningful Reduction of Disease-Associated Biomarker in Mice
CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>), a pioneering gene editing company, today shared in vivo proof of concept data supporting the development of a potentially first-in-class treatment for an undisclosed liver target in a poster presentation at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in New Orleans. Editas scientists will present the data in a poster session on Wednesday, May 14, 2025, 5:30 p.m. – 7:00 p.m. CT (6:30 p.m. – 8:00 p.m. ET).
An in vivo editing strategy using lipid nanoparticles (LNPs) with CRISPR/Cas RNA cargo was employed for an undisclosed liver target gene. The strategy mimics a naturally occurring, protective variant, resulting in upregulation of the target gene. This resulted in meaningful reduction in the clinically relevant disease-specific biomarker in mice.

EDIT

Editas Medicine Shares In Vivo Proof Of Concept Data Supporting Development Of Treatment For Undisclosed Liver Target In Poster Presentation At ASGCT Annual Meeting

BK Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BKTI#AMEX">BKTI</a>) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate of $0.44 by 54.55 percent. This is a 126.67 percent increase over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $19.05 million which beat the analyst consensus estimate of $17.00 million by 12.08 percent. This is a 4.51 percent increase over sales of $18.23 million the same period last year.

BK Technologies Q1 Adj. EPS $0.68 Beats $0.44 Estimate, Sales $19.05M Beat $17.00M Estimate

Bernstein on Tuesday issued a bullish note on Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) following its <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45365186/coinbase-stock-jumps-nearly-11-after-hours-monday-heres-why">inclusion in the S&amp;P 500</a>, projecting as much as $16 billion in potential capital inflows to the stock from both passive and active investment vehicles. 
What Happened: The note arrives just a day after the exchange announced that Coinbase will replace Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) in the index on May 19, making it the first cryptocurrency-focused company to join the benchmark.
In its analysis, Bernstein estimates that passive S&amp;P 500-linked ETFs and non-ETF funds could drive approximately $9 billion in inflows into Coinbase. 
An additional $7 billion is projected from active managers benchmarked to the S&amp;P 500 who may now be compelled to take positions in the stock. 
Coinbase currently holds a 0.1% weight in the S&amp;P 500 and represents about 0.7% of the financials sector by index allocation.
The note, authored by analyst Gautam Chhugani, described the development as a &#8220;dramatic turnaround&#8221; for a company that was recently entangled in litigation with the SEC, a case that has since been dropped. 
It also frames Coinbase&#8217;s entry into the index as symbolic of the broader shift in financial markets toward crypto legitimacy.
Bernstein reiterated its Outperform rating and maintained a price target of $310, citing strong earnings potential and continued dominance in U.S. crypto infrastructure. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45356864/cardano-up-23-in-7-days-as-co-founder-charles-hoskinson-explores-privacy-focused-stablecoin">Cardano Up 23% In 7 Days As Co-Founder Charles Hoskinson Explores Privacy-Focused Stablecoin</a>
Why It Matters: Coinbase currently trades at around $207 and has a market capitalization of approximately $53 billion.
The firm is forecast to grow earnings per share at a 38% compound annual growth rate, with Bernstein projecting 2026 EPS that is 70% above market consensus.
Coinbase went public in April 2021 via a direct listing and now processes over $1.5 billion in average daily trading volume, according to the report. 
The firm manages over $320 billion in assets and serves nearly 10 million monthly active users.
Coinbase's addition to the S&amp;P 500 becomes effective before trading opens on May 19, replacing Discover Financial Services.
It marks the first time a crypto-native firm enters the benchmark index, which includes companies like Apple, Microsoft and Amazon.
Coinbase originally listed on Nasdaq via direct listing in April 2021 and has since become the leading U.S.-regulated exchange for digital assets. 
Its S&amp;P 500 inclusion is expected to significantly broaden its exposure to institutional and passive capital flows.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45354779/stanford-warns-future-of-crypto-depends-on-regulation-quantum-safe-systems-digital-dollar-competition">Stanford Warns Future Of Crypto Depends On Regulation, Quantum-Safe Systems, Digital Dollar Competition</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Coinbase Could See Up To $16B Net Inflows After S&P 500 Entry: Bernstein

Legend Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.23) by 69.57 percent. This is a 69.57 percent increase over losses of $(0.23) per share from the same period last year. The company reported quarterly sales of $195.05 million which beat the analyst consensus estimate of $193.62 million by 0.74 percent. This is a 107.52 percent increase over sales of $93.99 million the same period last year.

LEGN

Legend Biotech Q1 Adj. EPS $(0.07) Beats $(0.23) Estimate, Sales $195.05M Beat $193.62M Estimate

Press Releases

BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin

Health Care

BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory Medicine

BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024

BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024

BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting

Financing

BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies

SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors

BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones

BeyondSpring Files 2024 Annual Report on Form 10-K

BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update

Comments

BeyondSpring

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL